A Novel Exonic Rearrangement Affecting MLH1 and the Contiguous LRRFIP2 is a Founder Mutation in Portuguese Lynch Syndrome Families
Overview
Authors
Affiliations
Purpose: Although Lynch syndrome is characterized by marked genetic heterogeneity, some specific mutations are observed at high frequency in well-defined populations or ethnic groups due to founder effects.
Methods: Genomic breakpoint identification, haplotype analysis, and mutation age determination were performed in 14 unrelated patients and 95 family members presenting the same MLH1 exonic rearrangement, among a series of 84 Lynch syndrome families with germline mutations in MLH1, MSH2, or MSH6.
Results: All 14 probands harbored an identical deletion, comprising exons 17-19 of the MLH1 gene and exons 26-29 of the LRRFIP2 gene, corresponding to the MLH1 mutation c.1896 + 280_oLRRFIP2:c.1750-678del. This mutation represents 17% of all deleterious mismatch repair mutations in our series. Haplotype analysis showed a conserved region of approximately 1 Mb, and the mutation age was estimated to be 283 ± 78 years. All 14 families are originated from the Porto district countryside.
Conclusion: We have identified a novel MLH1 exonic rearrangement that is a common founder mutation in Lynch syndrome families, indicating that screening for this rearrangement as a first step may be cost-effective during genetic testing of Lynch syndrome suspects of Portuguese ancestry, especially those originating from the Porto district.
Germline structural variant as the cause of Lynch Syndrome in a family from Ecuador.
Llargues-Sistac G, Bonjoch L, Munoz J, Dominguez-Rovira X, Ocana T, Alvarez-Mora M NPJ Genom Med. 2025; 10(1):3.
PMID: 39821083 PMC: 11739559. DOI: 10.1038/s41525-025-00462-y.
Genome sequencing identifies complex structural MLH1 variant in unsolved Lynch syndrome.
Witt D, Faust U, Strobl-Wildemann G, Sturm M, Buchert R, Zuleger T Mol Genet Genomic Med. 2023; 11(6):e2151.
PMID: 36760167 PMC: 10265068. DOI: 10.1002/mgg3.2151.
Mansour B, Donati M, Michalova K, Michal M, Ptakova N, Hajkova V Virchows Arch. 2022; 481(5):751-757.
PMID: 36171493 DOI: 10.1007/s00428-022-03418-0.
Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management.
Dork T, Hillemanns P, Tempfer C, Breu J, Fleisch M Cancers (Basel). 2020; 12(9).
PMID: 32854222 PMC: 7565375. DOI: 10.3390/cancers12092407.
Schneider N, Pastor T, de Paula A, Achatz M, Ribeiro Dos Santos A, Vianna F Cancer Med. 2018; 7(5):2078-2088.
PMID: 29575718 PMC: 5943474. DOI: 10.1002/cam4.1316.